GlassScriptPhysician profile
Richard E Seldeen
NPI 1326614223
$2,612.85
in general payments reported to CMS, 2019-2025
21 companies · $563 in 2025
The $563 reported for 2025 was more than what 77% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $359 · 2023: $1,005 · 2024: $686 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $386.92 | 2023-2024 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $323.74 | 2023-2024 | Spravato, Invega Sustenna |
| Amgen INC. | $239.11 | 2024-2025 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $233.25 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $223.97 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $222.82 | 2023-2025 | Austedo Xr |
| Alkermes, INC. | $132.42 | 2023-2024 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $116.50 | 2025 | Cobenfy |
| Genzyme Corporation | $111.58 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.11 | 2025 | Jardiance |
| Novo Nordisk INC | $87.02 | 2022 | |
| Stemline Therapeutics INC. | $83.07 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.13 | 2023 | |
| Medtronic, INC. | $71.43 | 2022 | |
| Corium, LLC | $68.31 | 2023 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $42.05 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $22.42 | 2023 | Ingrezza |
| Abbvie INC. | $16.47 | 2023 | |
| Neos Therapeutics, LP | $16.13 | 2023 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $14.98 | 2023 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $14.42 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Seldeen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.